BOARD OF DIRECTORS
Ms. Duncan currently serves on the Board of Directors, Audit Committee and Nominating and Corporate Governance Committee of Atea Pharmaceuticals, Inc. and Jounce Therapeutics, Inc. each a biopharmaceutical company. She also serves on the Boards of Directors and Audit Committees of Adaptimmune Therapeutics plc, ObsEva SA and Ovid Therapeutics, Inc., all biopharmaceutical companies.
Ms. Duncan holds an M.B.A. from the Wharton School of Business and a B.S. from Louisiana State University.
Mr. Khuong has served in a Board of Directors capacity of numerous public and private companies, including Arius Research (acquired by Roche), Durata (acquired by Actavis), Fusion Pharmaceuticals (NASDAQ: FUSN), Glaukos Medical (NYSE: GKOS), Intellia Pharmaceuticals (NASDAQ: NTLA), Intercept Pharmaceuticals (NASDAQ: ICPT), Inspire Medical Systems (NYSE: INSP), NextCure (NASDAQ: NXTC), Pieris (NASDAQ: PIRS), Rempex (acquired by Medicines Company), and ReViral. He holds a BS in molecular, cellular and developmental biology with a concentration in biotechnology and an MPH with a concentration in infectious diseases, both from Yale University.
Dr. Bergstrom holds an M.D. and a Ph.D. from the University of Washington, Seattle and a B.A. from the Johns Hopkins University.
Dr. Preston also currently serves on the Boards of Directors of Oxford Biomedica (LSE:OXB); Alder BioPharmaceuticals (NASDAQ:ALDR); Otonomy, Inc. (NASDAQ:OTIC); Entasis Therapeutics (NASDAQ:ETTX), Unchained Labs, Azura Opthalmics, and Karuna Therapeutics. She is an observer on the Board of Directors of Avalyn Pharmaceuticals. She has previously served on multiple Boards including Albireo (NASDAQ:ALBO), Aptalis Pharma (acquired by Forest Labs in 2014), and Elevation Pharmaceuticals (acquired by Sunovion in 2012). She was responsible for TPG Biotech’s investment in Par Pharmaceuticals (acquired by Endo Pharmaceuticals in 2015).
Dr. Preston earned an undergraduate degree in biochemistry from the University of London and a medical degree from the University of Oxford. She completed a post-doctoral fellowship in molecular biology at the Dana Farber Cancer Institute, Harvard University and trained in Internal Medicine at the Massachusetts General Hospital, Harvard and sub-specialized in Gastroenterology and Hepatology at UCSF. During her academic medical career, she was the recipient of a Fulbright Scholarship, a Fulbright Cancer Research Scholarship, a Harlech Scholarship and a Science and Engineering Research Council Post-doctoral Fellowship Award. Dr. Preston also serves on the Board of Trustees for the Harvard Discovery Council, the Fine Arts Museums of San Francisco, Saint Luke’s School and the Harlech Scholarship Foundation.
Dr. Christenson received his medical training at the Karolinska Institute and received his PhD in basic neuroscience in 1991. He served as a lecturer in neuroscience and also held a position as Assistant Dean at the Karolinska Institute Graduate School. Dr. Christenson has four years of clinical specialist training in paediatrics and paediatric neurology.
Prior to Fusion, Dr. Valliant founded the Centre for Probe Development and Commercialization (CPDC), a radiopharmaceutical research and development centre of excellence established in 2008 through funding from the Federal and Provincial governments, industry and academic partners. During his 10+ year tenure as CEO, the CPDC focused on discovering, developing and distributing the next generation of molecular imaging probes and therapeutic radiopharmaceuticals. The CPDC also plays an important role in Canada’s health care system, manufacturing and delivering a reliable, daily supply of imaging probes to hospitals and clinics nationally and internationally.
Dr. Valliant is also a Professor in the Department of Chemistry and Chemical Biology at McMaster University.
In 2009, Dr. Valiant was selected as one of Canada’s Top 40, Under 40, a distinction that recognizes his work at CPDC and McMaster University to advance molecular imaging probe technologies, improve patient care and spur economic growth through the commercialization of Canadian technologies. In 2015, he received the Brockhouse Canada Prize for Interdisciplinary Research in Science and Engineering from NSERC, recognizing his contribution to a team of researchers from physics, chemistry and nuclear medicine, who developed a breakthrough technology that uses hospital-based cyclotrons to produce critical medical isotopes.
Dr. Valliant completed his PhD at McMaster University, and followed with a post-doctoral fellowship under the joint supervision of professors Alun G. Jones (Harvard) and Alan Davison (MIT).
Before joining Rubius, Dr. Cagnoni served as President and Chief Executive Officer of Tizona Therapeutics, a privately held biotechnology company focused on developing next-generation immunotherapies for the treatment of cancer. He joined Tizona as the company’s first employee and grew the organization to support the filing of its first Investigational New Drug application. Prior to Tizona, he served as President of Onyx Pharmaceuticals (acquired by Amgen). Dr. Cagnoni joined Onyx in March 2013, as Executive Vice President, Global Research and Development and Technical Operations, and was named President in October 2013, when Onyx became an Amgen subsidiary. Previously, he was Senior Vice President and Global Head of Clinical Development at Novartis Oncology, Senior Vice President and Chief Medical Officer at Allos Therapeutics (acquired by Spectrum Pharmaceuticals) and, prior to that, Chief Medical Officer of OSI Pharmaceuticals (acquired by Astellas).
Earlier in his career, he served as Assistant Professor of Medicine, University of Colorado Bone Marrow Transplant Program, where he cared for patients undergoing stem cell transplants. Dr. Cagnoni earned his medical degree from University Buenos Aires School of Medicine, and he completed his fellowship in Hematology and Oncology at the Mount Sinai Medical Center, New York and a fellowship in Stem Cell Transplantation at the University of Colorado Health Sciences Center.
In addition to Rubius, Dr. Cagnoni is a member of the Board of Directors for Repertoire Immune Medicines and Tizona Therapeutics. He serves on the Board of Trustees for the Bay Area Discovery Museum and is a member of the Council on Foreign Relations. He previously served as a board member for CRISPR Therapeutics, Harpoon Therapeutics and Tango Therapeutics and was Executive Chairman of Blade Therapeutics.
Prior to joining Blueprint Medicines, Dr. Lee served as Head of U.S. Marketing at Algeta ASA, where she was the second hire in the U.S. In this role, she contributed to build the fully integrated organization that successfully launched Xofigo® (radium-223 dichloride), a first in class alpha-emitting radiopharmaceutical. Algeta was acquired by Bayer AG in 2014.
Earlier in her career, she held oncology marketing roles at Sanofi and Genzyme, driving global product launches and a mature product turnaround. As a healthcare strategy consultant at Health Advances, she advised biopharmaceutical and diagnostics clients bringing novel products to market.
Dr. Lee earned a B.S. in Biochemistry from the University of Alberta, and a Ph.D. in Cell Biology from the Massachusetts Institute of Technology. She conducted post-doctoral research in the lab of Jim Collins at Boston University.
Mr. Gannon currently serves on the Boards of Directors and as Chairman of the Audit Committees of Aerogen, enGene Inc., and LABORIE Medical Technologies, and on the Board of Directors and as a member of the Audit Committee of Xenon Pharmaceuticals. Previously, he served on the Board of Directors of Advanced Accelerator Applications SA. He received a bachelor of commerce from Concordia University in Montreal and completed the Executive Program at the Richard Ivey School of Business at the University of Western Ontario. Mr. Gannon is a Certified Public Accountant (CPA) and Chartered Accountant (CA).